Cytochrome P450 3A-mediated microsomal biotransformation of 1α,25-dihydroxyvitamin D3 in mouse and human liver: Drug-related induction and inhibition of catabolism

Drug Metabolism and Disposition

Volumn 40, Issue 5, 2012, Pages 907-918

  Deb, Subrata ^a,b   Pandey, Mitali ^a   Adomat, Hans ^a   Tomlinson Guns, Emma S ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b TRIPURA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; CLARITHROMYCIN; CYTOCHROME P450 1A1; CYTOCHROME P450 2B; CYTOCHROME P450 2C; CYTOCHROME P450 2D; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A11; CYTOCHROME P450 3A4; DEXAMETHASONE; DOCETAXEL; GLUCOCORTICOID; KETOCONAZOLE; PACLITAXEL; PREDNISONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; RITONAVIR; TAMOXIFEN; TAXANE DERIVATIVE; TRIAZOLAM; TROLEANDOMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG RETENTION; DRUG TRANSFORMATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; IC 50; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPECIES DIFFERENCE; VITAMIN D DEFICIENCY; VITAMIN METABOLISM;

ANIMALS; CALCITRIOL; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DEXAMETHASONE; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; PREDNISONE; SPECIES SPECIFICITY;

MUS;

EID: 84859887083     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041681     Document Type: Article

References (40)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE, and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. Xenobiotica 25:261-270.
2. Beckman MJ, Tadikonda P, Werner E, Prahl J, Yamada S, and DeLuca HF (1996) Human 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry 35:8465-8472. (Pubitemid 26240500)
3. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, et al. (2007) Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25:669-674. (Pubitemid 350002922)
4. Bodin K, Lindbom U, and Diczfalusy U (2005) Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta 1687:84-93. (Pubitemid 40228988)
5. Chang TK and Waxman DJ (2006) Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev 38:51-73. (Pubitemid 43738999)
6. Cheng JB, Motola DL, Mangelsdorf DJ, and Russell DW (2003) De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 278:38084-38093. (Pubitemid 37175340)
7. Czock D, Keller F, Rasche FM, and Häussler U (2005) Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 44:61-98. (Pubitemid 40096038)
8. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, Bush T, and Brooks JT (2011) Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 52:396-405.
9. Deeb KK, Trump DL, and Johnson CS (2007) Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7:684-700. (Pubitemid 47327412)
10. Dubois EF, Derks MG, Zwinderman AH, Dekhuijzen PN, Van Boxtel CJ, and Schweitzer DH (2003) Distinct actions of prednisolone and dexamethasone towards osteocalcin and eosinophilic cationic protein in assumed clinically equivalent doses: a study in healthy men. Eur J Clin Pharmacol 58:733-737. (Pubitemid 36399229)
11. Garland CF, Gorham ED, Mohr SB, and Garland FC (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19:468-483.
12. Gupta AK, Sauder DN, and Shear NH (1994) Antifungal agents: an overview. Part I. J Am Acad Dermatol 30:677-698. (Pubitemid 24157107)
13. Gupta RP, He YA, Patrick KS, Halpert JR, and Bell NH (2005) CYP3A4 is a vitamin D-24- and 25-hydroxylase: analysis of structure function by site-directed mutagenesis. J Clin Endocrinol Metab 90:1210-1219. (Pubitemid 40279256)
14. Gupta RP, Hollis BW, Patel SB, Patrick KS, and Bell NH (2004) CYP3A4 is a human microsomal vitamin D 25-hydroxylase. J Bone Miner Res 19:680-688. (Pubitemid 41071229)
15. Hashizume T, Xu Y, Mohutsky MA, Alberts J, Hadden C, Kalhorn TF, Isoherranen N, Shuhart MC, and Thummel KE (2008) Identification of human UDP-glucuronosyltransferases catalyzing hepatic 1alpha,25-dihydroxyvitamin D3 conjugation. Biochem Pharmacol 75:1240-1250.
16. Heel RC, Brogden RN, Carmine A, Morley PA, Speight TM, and Avery GS (1982) Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs 23:1-36. (Pubitemid 12133574)
17. Holick MF (2005) The vitamin D epidemic and its health consequences. J Nutr 135:2739S-2748S.
18. Hussain A, Dawson N, Amin P, Engstrom C, Dorsey B, Siegel E, and Guo C (2005) Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer. J Clin Oncol 23:2789-2796. (Pubitemid 46179469)
19. Inaba H and Pui CH (2010) Glucocorticoid use in acute lymphoblastic leukaemia. Lancet Oncol 11:1096-1106.
20. Ingraham BA, Bragdon B, and Nohe A (2008) Molecular basis of the potential of vitamin D to prevent cancer. Curr Med Res Opin 24:139-149. (Pubitemid 351160247)
21. Komuro S, Sato M, Kanamaru H, Kaneko H, Nakatsuka I, and Yoshitake A (1999) In vivo and in vitro pharmacokinetics and metabolism studies of 26,26,26,27,27,27-F6-1,25(OH)2 vitamin D3 (Falecalcitriol) in rat: induction of vitamin D3-24-hydroxylase (CYP24) responsible for 23S-hydroxylation in target tissues and the drop in serum levels. Xenobiotica 29:603-613. (Pubitemid 29332745)
22. Morris HA and Anderson PH (2010) Autocrine and paracrine actions of vitamin D. Clin Biochem Rev 31:129-138.
23. Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, and Trump DL (2002) Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther 72:648-659. (Pubitemid 36021004)
24. Newton DJ, Wang RW, and Lu AY (1995) Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
25. Ouellet D, Hsu A, Qian J, Lamm JE, Cavanaugh JH, Leonard JM, and Granneman GR (1998) Effect of fluoxetine on pharmacokinetics of ritonavir. Antimicrob Agents Chemother 42:3107-3112. (Pubitemid 28553726)
26. Paine MF, Hart HL, Ludington SS, Haining RL, Rettie AE, and Zeldin DC (2006) The human intestinal cytochrome P450 "pie." Drug Metab Dispos 34:880-886.
27. Prosser DE and Jones G (2004) Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29:664-673. (Pubitemid 39491265)
28. Reid IR and Heap SW (1990) Determinants of vertebral mineral density in patients receiving long-term glucocorticoid therapy. Arch Intern Med 150:2545-2548.
29. Rushmore TH and Kong AN (2002) Pharmacogenomics, regulation and signaling pathways of phase I and II drug metabolizing enzymes. Curr Drug Metab 3:481-490. (Pubitemid 34987481)
30. Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, Ohyama Y, and Inouye K (2000) Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 267:6158-6165.
31. Sakaki T, Sawada N, Nonaka Y, Ohyama Y, and Inouye K (1999) Metabolic studies using recombinant Escherichia coli cells producing rat mitochondrial CYP24. CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur J Biochem 262:43-48. (Pubitemid 29242607)
32. Schuster I (2011) Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814:186-199.
33. Sigmon JR, Yentzer BA, and Feldman SR (2009) Calcitriol ointment: a review of a topical vitamin D analog for psoriasis. J Dermatolog Treat 20:208-212.
34. Thummel KE and Wilkinson GR (1998) In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 38:389-430. (Pubitemid 28231501)
35. Verrotti A, Coppola G, Parisi P, Mohn A, and Chiarelli F (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 112:1-10.
36. Weiler HA, Wang Z, and Atkinson SA (1995) Dexamethasone treatment impairs calcium regulation and reduces bone mineralization in infant pigs. Am J Clin Nutr 61:805-811.
37. Xu Y, Hashizume T, Shuhart MC, Davis CL, Nelson WL, Sakaki T, Kalhorn TF, Watkins PB, Schuetz EG, and Thummel KE (2006) Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia. Mol Pharmacol 69:56-65. (Pubitemid 43048893)
38. Yu C, Chai X, Yu L, Chen S, and Zeng S (2011) Identification of novel pregnane X receptor activators from traditional Chinese medicines. J Ethnopharmacol 136:137-143.
39. Zhang H, Davis CD, Sinz MW, and Rodrigues AD (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opin Drug Metab Toxicol 3:667-687. (Pubitemid 351320636)
40. Zhou C, Assem M, Tay JC, Watkins PB, Blumberg B, Schuetz EG, and Thummel KE (2006) Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116:1703-1712.